330945-07-8

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 100-39-0 benzyl bromide 
• 4298-08-2 trans-3-hydroxy-L-proline 
• 187039-57-2 (2S,3S)-1-(tert-butoxycarbonyl)-3-hydroxypyrrolidine-2-carboxylic acid 

Downstream Products

• 871981-52-1 ((3S)-acetoxy-1-tert-butoxycarbonyl-(2S)-pyrrolidinyl)carboxylic acid benzyl ester 
• 330945-21-6 2-benzyl 1-(tert-butyl) (2R,3S)-3-fluoropyrrolidine-1,2-dicarboxylate 
• 330945-23-8 (2R,3S)-1-tert-butoxycarbonyl-3-fluoro-pyrrolidine-2-carboxylic acid 
• 186132-95-6 2-benzyl 1-(tert-butyl)(2S,3R)-3-hydroxypyrrolidine-1,2-dicarboxylate 
• 936703-36-5 C₅₇H₇₄N₆O₁₅ 
• 936703-32-1 C₂₄H₃₅N₃O₈ 
• 330945-11-4 2-benzyl 1-(tert-butyl) (2R,3R)-3-fluoropyrrolidine-1,2-dicarboxylate 

Relevant academic research and scientific papers

Synthesis of optically pure N-Boc-protected (2R,3R)- and (2R,3S)-3-fluoroprolines

Non-protein amino acids (2R,3R)- and (2R,3S)-3-fluoroprolines were synthesized as novel probes for studying the cis/trans isomerization of the amino acyl-proline peptide bond. The N-Boc-protected target compounds were obtained as optically pure material s

SUBSTITUTED OXOPYRIDINE DERIVATIVES

The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF

The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

VLA-4 INHIBITOR

A compound which selectively inhibits bonding between a ligand and α4β1 integrin (VLA-4); a process for producing the compound; and a medicine containing the compound. The compound is one represented by, e.g., the formula (I) or a salt thereof. Also provided is a preventive and/or therapeutic agent which contains the compound or salt as a major component and is effective against diseases attributable to cell adhesion, such as, e.g., inflammatory reaction, autoimmune disease, cancer metastasis, bronchial asthma, nasal obstruction, diabetes, arthritis, psoriasis, multiple sclerosis, inflammatory intestinal disease, and rejection reaction in transplantation. (In the formula, Y1 represents arylene, etc.; V1 represents aryl, etc.; and R11 to R14 each represents H, OH, halogeno, etc.)